Placebo-controlled study of rTMS for the treatment of Parkinson's disease

Mikhail P. Lomarev, Sulada Kanchana, William Bara-Jimenez, Meena Iyer, Eric M. Wassermann, Mark Hallett

Research output: Contribution to journalArticlepeer-review

190 Scopus citations


The objective of this study is to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for gait and bradykinesia in patients with Parkinson's disease (PD). In a double-blind placebo-controlled study, we evaluated the effects of 25 Hz rTMS in 18 PD patients. Eight rTMS sessions were performed over a 4-week period. Four cortical targets (left and right motor and dorsolateral prefrontal cortex) were stimulated in each session, with 300 pulses each, 100% of motor threshold intensity. Left motor cortex (MC) excitability was assessed using motor evoked potentials (MEPs) from the abductor pollicis brevis. During the 4 weeks, times for executing walking and complex hand movements tests gradually decreased. The therapeutic rTMS effect lasted for at least 1 month after treatment ended. Right-hand bradykinesia improvement correlated with increased MEP amplitude evoked by left MC rTMS after individual sessions, but improvement overall did not correlate with MC excitability. rTMS sessions appear to have a cumulative benefit for improving gait, as well as reducing upper limb bradykinesia in PD patients. Although short-term benefit may be due to MC excitability enhancement, the mechanism of cumulative benefit must have another explanation.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalMovement Disorders
Issue number3
StatePublished - Mar 2006


  • Motor cortex
  • Parkinson's disease
  • rTMS


Dive into the research topics of 'Placebo-controlled study of rTMS for the treatment of Parkinson's disease'. Together they form a unique fingerprint.

Cite this